Neurogenic Bladder

Name: Neurogenic Bladder
Creator: Dr. Marinos Vasilas

My Clinical Approach

Neurogenic bladder requires systematic, lifelong follow-up. Kidney safety first, continence next, quality of life third.

I follow the EAU Guidelines on Neuro-Urology 2024 and ICS recommendations:

Video-urodynamics as the cornerstone of diagnosis — assesses detrusor, sphincter, reflux.
Detection of the hostile bladder: filling pressure >40 cmH₂O, poor compliance, reflux.
Clean intermittent catheterisation (CIC) 4-6 times/day as the foundation.
Intravesical onabotulinumtoxinA 200 U for refractory neurogenic detrusor overactivity.
Sacral neuromodulation for selected patients with intact spinal cord.
Augmentation cystoplasty (enterocystoplasty) for low capacity/compliance despite the above.
Multidisciplinary collaboration with neurologist, rehabilitation physician, specialist nurse.

What is neurogenic bladder

Neurogenic bladder is storage or voiding dysfunction of the urinary bladder due to central or peripheral nervous system injury. The bladder and sphincter are controlled by brainstem, sacral spinal (S2-S4) and autonomic centres — any disruption affects function.

ICS Classification

Neurogenic detrusor overactivity

Involuntary detrusor contractions during filling. Characteristic of suprasacral lesions (SCI above T12, MS, stroke).

Detrusor underactivity / areflexia

Weak or absent contraction. Characteristic of lesions below T12, sacral, diabetic neuropathy, post-pelvic surgery.

Detrusor-sphincter dyssynergia (DSD)

Simultaneous detrusor and sphincter contraction — high pressures, functional obstruction. Dangerous to upper urinary tract.

Sphincter dyssynergia

Failure of the sphincter to relax during contraction or to contract during filling — incontinence or retention.

Causes

Spinal cord injury (SCI) — the classic cause; behaviour depends on level and completeness.
Multiple sclerosis (MS) — 50-80% of patients develop symptoms.
Parkinson’s disease / multiple system atrophy (MSA).
Stroke — often detrusor overactivity.
Spina bifida / myelomeningocele — paediatric.
Diabetic neuropathy — underactivity, increasing residual.
Surgical pelvic injury: radical hysterectomy, abdominoperineal resection.
Alzheimer’s disease / dementia — functional incontinence.
Spinal tumours, myelodysplasia, cauda equina syndrome.

Symptoms

Storage symptoms

Frequency, nocturia, urgency, urge incontinence.

Voiding symptoms

Weak stream, intermittent stream, sense of incomplete emptying, chronic retention, overflow incontinence.

Associated

Recurrent urinary infections, bladder stones, haematuria, lumbar/pelvic discomfort.

Autonomic dysreflexia (SCI >T6)

Sudden hypertension, severe headache, sweating, nausea — emergency.

Diagnosis

History + neurological assessment

Primary diagnosis, lesion level (if SCI), drug profile, hand function (for CIC).

3-day voiding diary

Volumes, frequency, incontinence episodes, fluid intake — foundation for interventions.

Physical exam + reflexes

Perineal sensation S2-S4, bulbocavernosus reflex, anal tone, lumbar palpation.

Urinalysis + urine culture

Exclude infection. Chronic asymptomatic bacteriuria is common — do not treat with rare exceptions.

Renal function (creatinine + eGFR)

Monitor chronic kidney disease at every visit.

Renal + bladder ultrasound

Hydronephrosis, post-void residual, wall thickness. First-line imaging.

Video-urodynamics

Gold standard: assesses capacity, compliance, overactivity, DSD, reflux. Repeat every 1-2 years.

Spinal / brain MRI

When no known neurological disease (new diagnosis) or rapidly worsening symptoms.

DMSA scan

Split renal function assessment — in patients with hydronephrosis or high risk.

Treatment

Aims (per EAU 2024): (1) upper urinary tract protection, (2) continence, (3) quality of life, (4) infection avoidance.

1. Clean intermittent catheterisation (CIC)

Foundation of treatment. 4-6 times/day, 14-Fr hydrophilic or pre-lubricated catheters. Training by a specialist nurse.

2. Pharmacotherapy

• Antimuscarinics (solifenacin, tolterodine, trospium): first line for overactivity.
• Mirabegron / beta-3 agonists: alternative with fewer side effects.
• Alpha-blockers: improve voiding.
• Desmopressin: for nocturnal polyuria (selectively).

3. Intravesical onabotulinumtoxinA 200 U

For refractory neurogenic detrusor overactivity. 30 injection sites, duration 6-9 months, high efficacy. Most patients require CIC afterwards (~30%).

4. Sacral neuromodulation

For selected patients with detrusor over- or underactivity and intact sacral roots. Not in complete SCI.

5. Augmentation cystoplasty (enterocystoplasty)

For low capacity or poor compliance despite maximal conservative treatment. Uses an ileal segment. Lifelong CIC required.

6. Brindley stimulation + posterior rhizotomy

For complete SCI in specialist centres. Implanted sacral root stimulator + posterior rhizotomy for areflexic bladder.

7. Ileal conduit urinary diversion

Last resort to save the kidneys — usually in advanced CKD, inability to perform CIC, refractory infections.

Complications

Hydronephrosis — from high intravesical pressure or vesicoureteral reflux.
Chronic kidney disease — ~20% of untreated patients progress to ESRD within 10 years.
Recurrent urinary infections — but chronic asymptomatic bacteriuria is NOT treated.
Bladder & kidney stones.
Autonomic dysreflexia — SCI >T6, emergency.
Bladder cancer — increased risk with chronic catheterisation >10 years.
Post-enteroplasty complications: metabolic acidosis, stones, perforation.

Follow-up

Every 6-12 months: renal + bladder ultrasound, creatinine, eGFR, post-void residual.
Urine culture only when symptomatic.
Video-urodynamics every 1-2 years or with deterioration.
DMSA / DTPA in hydronephrosis or eGFR drop.
Annual cystoscopy after 10 years of chronic catheterisation.
Psychosocial support, carer education.

Frequently Asked Questions (FAQ)

What is neurogenic bladder?

Neurogenic bladder is bladder dysfunction due to neurological injury. It can present as detrusor overactivity, underactivity or detrusor-sphincter dyssynergia (DSD), with risk to the upper urinary tract.

Which conditions cause it?

Spinal cord injury (SCI), multiple sclerosis (MS), Parkinson’s disease, stroke, spina bifida, diabetic neuropathy, surgical pelvic injury (radical hysterectomy, abdominoperineal resection), Alzheimer’s disease.

What are the symptoms?

Urgency, incontinence, chronic retention, recurrent urinary infections, oliguria or frequency. In high SCI: autonomic dysreflexia (sudden hypertension, headache, sweating).

How is it diagnosed?

Full history + neurological examination + 3-day voiding diary. Ultrasound with post-void residual. Video-urodynamics is the gold standard. MRI of the spine, renal CT/ultrasound, DMSA scan.

How is it treated?

Aim: upper urinary tract protection, continence, quality of life. Pyramid: clean intermittent catheterisation (CIC), antimuscarinics / beta-3 (mirabegron), intravesical onabotulinumtoxinA 200 U, sacral neuromodulation, augmentation cystoplasty, Brindley stimulation.

Why is it dangerous?

Chronic high intravesical pressure is transmitted to the kidneys → hydronephrosis, vesicoureteral reflux, chronic kidney disease, acute kidney injury. If untreated, ~20% reach end-stage renal disease within 10 years.

Is catheterisation forever?

Often yes, but with clean intermittent catheterisation (CIC) 4-6 times per day — not an indwelling catheter. CIC is the safest method for the upper urinary tract.

How often is follow-up?

Every 6-12 months: renal ultrasound, post-void residual, creatinine, urine culture as needed. Urodynamics every 1-2 years or with deterioration. In newly diagnosed SCI: urodynamics at 3, 6 and 12 months.